A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...
Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.
People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...
Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...
AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the ...
People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...
Individuals with early-onset COPD and rapidly progressive pre-COPD frequently have a decades-long history of impaired ...
Physicians recommend that patients with chronic obstructive pulmonary disease (COPD) quit smoking and use steroids, ...